PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer.

NPJ Breast Cancer · 2019 · PMC6757060 · PMID 31552290

Europe PMC DOI

hedged sentences

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

a trend toward significancep = 0.07so close (0.05 < p ≤ 0.1)

Overall in the combined analysis of both trials, there was a trend toward significance ( p = 0.07, 1-tailed Fisher’s exact) for an association of luminal A status with clinical benefit to PI3K inhibition plus estrogen suppression with letrozole.

also in 3,729 other papers

showed a trendp = 0.07so close (0.05 < p ≤ 0.1)

PIK3CA -mutant PDX models showed a trend toward an improved response to alpelisib as well (one-tailed p = 0.07).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.